Releases Details

Grant of Options and PDMR Dealing

Mar 28, 2022

RNS Number : 2646G

MaxCyte, Inc.

28 March 2022

The following amendments have been made to the Grant of Options and PDMR Dealing announcement released on 28 March 2022 at 07:00 under RNS number 1548G.

An incorrect Identification Code in section 4.b has been removed.

Section 4.c, Nature of the transaction, has been amended to "Grant of Options" instead of "Exercise of options and Sale of Common Stock by PDMR".

All other details remain unchanged.

The full amended text is shown below.

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options and PDMR Dealing

Gaithersburg, Maryland - 28 March 2022: MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that on 25 March 2022, a total of 642,000 options of common stock in the Company ("Common Stock") were granted to PDMRs who are officers of the Company ("Option Grants"). Details of the Option Grants are given below:

Option Grants to PDMRs
Doerfler, Doug	500,000
Murphy, Amanda	142,000
Total	642,000

Option Grants vest 12/48th of the total grant one year after date of grant, and thereafter vest 1/48^th per month for 36 months after the date of grant. The Option Grants have an exercise price of $7.12 equal to the closing price of Maxcyte's stock on the Nasdaq Stock Exchange on 25 March 2022.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Doerfler, Doug Murhphy, Amanda
2	Reason for the notification
a)	Position/status	Doerfler, Doug - CEO and Director Murphy, Amanda - CFO
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Grant of Options over Shares of Common Stock
b)	Identification Code
c)	Nature of the transaction	Grant of Options
d)	Price(s) and volume(s)	Doerfler, Doug - 500,000 at an exercise price of $7.12 Murphy, Amanda - 142,000 at an exercise price of $7.12

e)	Aggregated information - Aggregated volume - Price	N/A N/A N/A
f)	Date of the transaction	25 March 2022
g)	Place of the transaction	Nasdaq Stock Exchange

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation^® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

For further information, please contact:

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Accounting Officer

+1 301 944 1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

+44 (0)20 7260 1000

Joint Corporate Broker

Stifel Nicolaus Europe Limited

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams

+44 (0) 20 7710 7600

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

+44 (0)203 709 5700

maxcyte@consilium-comms.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBDGDXLBDDGDI